Printer Friendly

SI-Bone's iFuse Implant System Cleared by the US FDA.

M2 PHARMA-November 9, 2015-SI-Bone's iFuse Implant System Cleared by the US FDA


- The US Food and Drug Administration has cleared US-based medical device company SI-Bone, Inc.'s iFuse Implant System, a minimally invasive surgical device indicated for fusion for certain disorders of the sacroiliac joint, to include in its indication statement that "Clinical studies have demonstrated that treatment with the iFuse Implant System improved pain, patient function and quality of life at 12 months post-implantation," the company said.

This addition was based on prospective and retrospective clinical studies demonstrating consistent improvement in pain, patient function and quality of life at 12-months in patients treated with iFuse.

SI-Bone is a sacroiliac joint medical device company focused on the development of tools and products for patients with low back issues related to certain SI joint disorders.

The company develops, manufactures and markets minimally invasive products for patients with these disorders.

SI-Bone received original 510(k) clearance in November 2008from the Food and Drug Administration to market its iFuse Implant System.

The CE mark for European commercialisation was obtained in November 2010.

SI-Bone's iFuse Implant System is a minimally invasive surgical option that uses titanium implants coated with a porous, titanium plasma spray that acts as an interference surface, designed to help decrease implant motion, provide immediate fixation and allow for biological fixation to support long term fusion.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.

This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than six months.

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Clinical report
Date:Nov 9, 2015
Previous Article:Sciex Launches High Performance CESI-MS Platform.
Next Article:Cardiac Science Receives Order for 85 Powerheart G5 Automated External Defibrillators.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters